ptx-logo .png
Prelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare Conferences
September 06, 2022 08:00 ET | Prelude Therapeutics, Inc.
WILMINGTON, Del., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will be...
ITM_Logo_Claim_RGB_high-res.png
ITM to Present Trial Design of Ongoing Phase III COMPOSE Study in Advanced Neuroendocrine Tumors at ESMO 2022
September 06, 2022 05:00 ET | ITM Isotope Technologies Munich SE
Garching / Munich, September 6, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that a scientific poster on the design of its second...
ITM_Logo_Claim_RGB_high-res.png
ITM Acquires a New Platform for the Development of Next-Generation Theranostics
August 18, 2022 05:18 ET | ITM Isotope Technologies Munich SE
• Technology platform for PET tracers strengthens ITM’s radiodiagnostic portfolio • Additional assets potentially expand ITM’s pipeline of novel targeted radionuclide therapeutics Garching /...
22157.jpg
Global Genomic Cancer Panel and Profiling Market Research Report 2022
July 27, 2022 06:13 ET | Research and Markets
Dublin, July 27, 2022 (GLOBE NEWSWIRE) -- The "Genomic Cancer Panel and Profiling Markets by Cancer, by Application, by Tissue and by Gene Type With Screening Potential Market Size, Customized...
ITM Appoints Dr. Sebastian Marx as Chief Business Officer and Member of Executive Board
July 22, 2022 05:00 ET | ITM Isotope Technologies Munich SE
Garching / Munich, July 22, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Sebastian Marx to its Executive Board...
Florida Cancer Specialists & Research Institute Furthers Commitment to Clinical Research & Innovation, Next Generation Sequencing in Advancement of Cancer Care; Adds New In-House, Precision Oncology Capabilities
July 21, 2022 10:13 ET | Florida Cancer Specialists & Research Institute
Fort Myers, Fla., July 21, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute, LLC (FCS) today announced the formation of additional precision oncology capabilities and...
ITM_Logo_Claim_RGB_high-res.png
ITM Signs Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177
July 21, 2022 05:21 ET | ITM Isotope Technologies Munich SE
ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Y-mAbs’ Targeted Radionuclide Therapy candidate GD2-SADA: 177Lu-DOTA Complex for GD2-positive...
ITM_Logo_Claim_RGB_high-res.png
ITM: New Isotope Production System at Bruce Power Successfully Produces First Medical Isotope
June 21, 2022 11:45 ET | ITM Isotope Technologies Munich SE
First-of-a-kind Isotope Production System continues to progress towards commercial, industrial-scale production of medical isotopes for cancer therapeutics ONTARIO, CANADA, and MUNICH, GERMANY – June...
Breast Cancer Society of Canada Grants $250,000 To Precision Oncology Research at Dalhousie University
June 15, 2022 10:32 ET | The Breast Cancer Society of Canada
SARNIA, Ontario, June 15, 2022 (GLOBE NEWSWIRE) -- The Breast Cancer Society of Canada (BCSC) today announced $250,000 in funding to the Department of Biochemistry and Molecular Biology, Faculty of...
Breast Cancer Society of Canada Grants $350,000 To Precision Oncology Research
May 25, 2022 09:24 ET | The Breast Cancer Society of Canada
SARNIA, Ontario, May 25, 2022 (GLOBE NEWSWIRE) -- The Breast Cancer Society of Canada (BCSC) today announced the recipients of their first-ever Breast Cancer Research request for proposals....